Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3031% above fair value
$41.37−2.28 (-5.22%)
Close on Nov 20, 2026Market cap $5.84BP/E –Yield –
Arrowhead Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Arrowhead Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$75.11M. For fiscal 2025 it was $156.89M. The highest annual figure on record is $161.03M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $156.89M | – |
| FY2024 | Sep 30, 2024 | -$604.32M | – |
| FY2023 | Sep 30, 2023 | -$330.63M | – |
| FY2022 | Sep 30, 2022 | -$188.91M | -227.9% |
| FY2021 | Sep 30, 2021 | $147.75M | – |
| FY2020 | Sep 30, 2020 | -$107.75M | -166.9% |
| FY2019 | Sep 30, 2019 | $161.03M | – |
| FY2018 | Sep 30, 2018 | -$48.64M | – |
| FY2017 | Sep 30, 2017 | -$31.86M | – |
| FY2016 | Sep 30, 2016 | -$68.29M | – |
| FY2015 | Sep 30, 2015 | -$67.68M | – |
| FY2014 | Sep 30, 2014 | -$37.13M | – |
| FY2013 | Sep 30, 2013 | -$19.33M | – |
| FY2012 | Sep 30, 2012 | -$15.82M | – |
| FY2011 | Sep 30, 2011 | -$7.67M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$181.32M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $81.88M | -82.0% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $11.33M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $13.00M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$157.08M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $454.76M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$153.79M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$161.51M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$129.87M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$126.45M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$186.50M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$89.83M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$67.38M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$58.99M | -201.7% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$114.43M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$101.45M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$78.35M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $57.98M | -77.4% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$67.09M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$32.23M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$33.54M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $256.71M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$43.19M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$13.15M | -319.8% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$35.56M | -587.0% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$31.19M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$27.85M | -116.6% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $5.98M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $7.30M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$19.80M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $167.55M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$3.39M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$14.61M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$15.82M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$14.83M | -415.2% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$9.31M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$11.57M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$15.68M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $4.70M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$12.89M | – |
See a number that looks wrong?